These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38215228)

  • 1. Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist.
    Moore E; Bell IM; Fraley ME; Burgey CS; White RB; Li CC; Regan CP; Danziger A; McGaraughty SP; Naseri Kouzehgarani G; Salvatore C; Banerjee P
    Cephalalgia; 2024 Jan; 44(1):3331024231226186. PubMed ID: 38215228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.
    Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L
    Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor.
    Moore E; Fraley ME; Bell IM; Burgey CS; White RB; Li CC; Regan CP; Danziger A; Stranieri Michener M; Hostetler E; Banerjee P; Salvatore C
    J Pharmacol Exp Ther; 2020 Jan; ():. PubMed ID: 31992609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
    Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
    Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman JM
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.
    Shi L; Lehto SG; Zhu DX; Sun H; Zhang J; Smith BP; Immke DC; Wild KD; Xu C
    J Pharmacol Exp Ther; 2016 Jan; 356(1):223-31. PubMed ID: 26559125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists.
    Johnson KW; Li X; Huang X; Heinz BA; Yu J; Li B
    Headache; 2022 Jul; 62(7):848-857. PubMed ID: 35822594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.
    Salvatore CA; Moore EL; Calamari A; Cook JJ; Michener MS; O'Malley S; Miller PJ; Sur C; Williams DL; Zeng Z; Danziger A; Lynch JJ; Regan CP; Fay JF; Tang YS; Li CC; Pudvah NT; White RB; Bell IM; Gallicchio SN; Graham SL; Selnick HG; Vacca JP; Kane SA
    J Pharmacol Exp Ther; 2010 Apr; 333(1):152-60. PubMed ID: 20065019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
    Li CC; Vermeersch S; Denney WS; Kennedy WP; Palcza J; Gipson A; Han TH; Blanchard R; De Lepeleire I; Depré M; Murphy MG; Van Dyck K; de Hoon JN
    Br J Clin Pharmacol; 2015 May; 79(5):831-7. PubMed ID: 25377933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A; Balasundaram MK
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Presence of Calcitonin Gene-Related Peptide and Its Receptors in Rat, Pig and Human Brain: Species Differences in Calcitonin Gene-Related Peptide Pharmacology.
    Warfvinge K; Edvinsson L; Pickering DS; Sheykhzade M
    Pharmacology; 2019; 104(5-6):332-341. PubMed ID: 31484177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay.
    Hershey JC; Corcoran HA; Baskin EP; Salvatore CA; Mosser S; Williams TM; Koblan KS; Hargreaves RJ; Kane SA
    Regul Pept; 2005 Apr; 127(1-3):71-7. PubMed ID: 15680472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.